» Articles » PMID: 38409642

Mechanism of Efferocytosis in Determining Ischaemic Stroke Resolution-Diving into Microglia/Macrophage Functions and Therapeutic Modality

Overview
Journal Mol Neurobiol
Date 2024 Feb 27
PMID 38409642
Authors
Affiliations
Soon will be listed here.
Abstract

After ischaemic cerebral vascular injury, efferocytosis-a process known as the efficient clearance of apoptotic cells (ACs) by various phagocytes in both physiological and pathological states-is crucial for maintaining central nervous system (CNS) homeostasis and regaining prognosis. The mechanisms of efferocytosis in ischaemic stroke and its influence on preventing inflammation progression from secondary injury were still not fully understood, despite the fact that the fundamental process of efferocytosis has been described in a series of phases, including AC recognition, phagocyte engulfment, and subsequent degradation. The genetic reprogramming of macrophages and brain-resident microglia after an ischaemic stroke has been equated by some researchers to that of the peripheral blood and brain. Based on previous studies, some molecules, such as signal transducer and activator of transcription 6 (STAT6), peroxisome proliferator-activated receptor γ (PPARG), CD300A, and sigma non-opioid intracellular receptor 1 (SIGMAR1), were discovered to be largely associated with aspects of apoptotic cell elimination and accompanying neuroinflammation, such as inflammatory cytokine release, phenotype transformation, and suppressing of antigen presentation. Exacerbated stroke outcomes are brought on by defective efferocytosis and improper modulation of pertinent signalling pathways in blood-borne macrophages and brain microglia, which also results in subsequent tissue inflammatory damage. This review focuses on recent researches which contain a number of recently discovered mechanisms, such as studies on the relationship between benign efferocytosis and the regulation of inflammation in ischaemic stroke, the roles of some risk factors in disease progression, and current immune approaches that aim to promote efferocytosis to treat some autoimmune diseases. Understanding these pathways provides insight into novel pathophysiological processes and fresh characteristics, which can be used to build cerebral ischaemia targeting techniques.

Citing Articles

Extracellular cold-inducible RNA-binding protein in CNS injury: molecular insights and therapeutic approaches.

Lapin D, Sharma A, Wang P J Neuroinflammation. 2025; 22(1):12.

PMID: 39838468 PMC: 11752631. DOI: 10.1186/s12974-025-03340-7.


Efferocytosis: the resolution of inflammation in cardiovascular and cerebrovascular disease.

Zhang B, Zou Y, Yuan Z, Jiang K, Zhang Z, Chen S Front Immunol. 2024; 15:1485222.

PMID: 39660125 PMC: 11628373. DOI: 10.3389/fimmu.2024.1485222.

References
1.
Walter K . What Is Acute Ischemic Stroke?. JAMA. 2022; 327(9):885. DOI: 10.1001/jama.2022.1420. View

2.
Parvez S, Kaushik M, Ali M, Alam M, Ali J, Tabassum H . Dodging blood brain barrier with "nano" warriors: Novel strategy against ischemic stroke. Theranostics. 2022; 12(2):689-719. PMC: 8692911. DOI: 10.7150/thno.64806. View

3.
Wang L, Zhu T, Xu H, Pu X, Zhao X, Tian F . Effects of notoginseng leaf triterpenes on small molecule metabolism after cerebral ischemia/reperfusion injury assessed using MALDI-MS imaging. Ann Transl Med. 2021; 9(3):246. PMC: 7940900. DOI: 10.21037/atm-20-4898. View

4.
Yu H, Chen X, Guo X, Chen D, Jiang L, Qi Y . The clinical value of serum xanthine oxidase levels in patients with acute ischemic stroke. Redox Biol. 2023; 60:102623. PMC: 9932569. DOI: 10.1016/j.redox.2023.102623. View

5.
Nakahashi-Oda C, Fujiyama S, Nakazawa Y, Kanemaru K, Wang Y, Lyu W . CD300a blockade enhances efferocytosis by infiltrating myeloid cells and ameliorates neuronal deficit after ischemic stroke. Sci Immunol. 2021; 6(64):eabe7915. DOI: 10.1126/sciimmunol.abe7915. View